An interventional study of 72-hour ejaculation abstinence, followed by ejaculation in Prostate Cancer, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Prostatic Neoplasms by University Health Network, Toronto — 23 open to participants now, 29 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.
Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 67th largest by planned enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2026, is one of 44 with no phase, reaches primary completion later than 9 of the 28 other live ones, and was the 102nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →23 of the 102 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18–100 · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 40–85 · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 35 · Phase 3 4 · Phase 4 2
First in 1999; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 44 across the 86 interventional studies, 82 across the 13 observational. Of the 67 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,439 studies on the registry; 296 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
8 of the studies in Prostatic Neoplasms by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06877598University Health Network, TorontoCanada-wide Implementation of a Virtual Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners | 2026-12 |
| NCT05033301University Health Network, TorontoEvaluating the Effectiveness of the Nurse Ned Clinic | 2026-12-30 |
| NCT05582772University Health Network, TorontoTOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer | 2027-02-28 |
| NCT00913939University Health Network, TorontoHigh-Dose-Rate Brachytherapy | 2027-05 |
| NCT07747493University Health Network, Toronto68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy | 2027-07-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure how ejaculation changes the size, shape and position of the seminal vesicles on MRI and CT scans, and whether these changes could affect radiation treatment planning.
Participants will be aksed to not ejaculate for at least 3 days prior to the visit. On the day of the visit, participants will complete standard of care MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans. These scans are already used in medical care but would not normally be done more than once before receiving radiation treatment. The second set of scans CT and MRI are part of the study will occur on the same day, 30-60 minutes after you ejaculate into a provided container.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Each participant will serve as their own control. Participants with prostate cancer undergoing standard-of-care (SOC) MR and CT simulation for radiotherapy planning will be approached. Following a standardized period of ejaculatory abstinence (i.e., \> 72hrs), the patient's SOC MR simulation and CT simulation will provide the baseline pre-ejaculation imaging datasets. After completion of the baseline simulation imaging, participants will undergo masturbation-induced ejaculation in a private setting, collect the ejaculate into a pre-weighed specimen container, and undergo repeat research imaging beginning approximately 30-60 minutes following ejaculation.
Behavioral: 72-hour ejaculation abstinence, followed by ejaculation
Before baseline imaging, participants will be asked to not ejaculate for at least 72 hours. After baseline imaging, participants will undergo masturbation-induced ejaculation, which will be followed by repeat research imaging.
Change in Total Seminal Vesicle Volume
Paired absolute and relative change in total seminal vesicle volume on MR from pre-ejaculation to post-ejaculation
Time frame: From baseline imaging to repeat research imaging (1 day)
Change in Right, Left, Combined and Proximal Seminal Vesicle Volume
Right/left and proximal seminal vesicle volume change from pre-ejaculation to post-ejaculation
Time frame: From baseline imaging to repeat research imaging (1 day)
Association of Ejaculation and Changes in Seminal Vesicle Shape and Position
Dice similarity coefficient, surface-distance and centroid-displacement metrics to measure contour overlap, surface distance, centroid displacement and orientation/angulation
Time frame: From baseline imaging to repeat research imaging (1 day)
Correlation between Ejaculate Volume with absolute and relative seminal vesicle volume change and seminal vesicle emptying fraction
Ejaculate mass collected from masturbation-induced ejaculation will be weighed in grams and used as an estimate of ejaculate volume in milliliters. Correlation will be assessed using Pearson or Spearman correlation, with simple linear regression used descriptively.
Time frame: From baseline imaging to repeat research imaging (1 day)
Impact of ejaculation and imaging condition on inter-observer and intra-observer seminal vesicle contouring variability
Intra- and inter-observer contouring variability on MR alone, CT alone and CT with co-registered MRI available for review
Time frame: From baseline imaging to repeat research imaging (1 day)
Estimate the dosimetric impact of post-ejaculatory seminal vesicle changes
Changes in selected target-coverage and organ-at-risk dosimetric metrics
Time frame: From baseline imaging to repeat research imaging (1 day)
Compare ejaculation-associated seminal vesicle volumetric and geometric changes and characterize agreement between modalities
Paired CT-based volumetric/geometric change and MR-CT agreement
Time frame: From baseline imaging to repeat research imaging (1 day)
Determine whether access to co-registered MR during CT-based contouring improves seminal vesicle delineation reproducibility and preserves detection of ejaculation-associated anatomical change compared with CT alone
Incremental effect of MR fusion on CT-based contouring reproducibility
Time frame: From baseline imaging to repeat research imaging (1 day)
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.
Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →